

AWARD NUMBER: **W81XWH-13-1-0122**

TITLE: **Potential of Targeting PDE1C/2A for Suppressing Metastatic Ovarian Cancers**

PRINCIPAL INVESTIGATOR: Shuang Huang

CONTRACTING ORGANIZATION:
GEORGIA HEALTH SCIENCES UNIVERSITY RESEARCH
INSTITUTE, INC.

Augusta, GA 30912

REPORT DATE: July 2014

TYPE OF REPORT: Annual Report

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE July 2014		2. REPORT TYPE Annual		3. DATES COVERED 15 Jun 2013 - 14 Jun 2014	
4. TITLE AND SUBTITLE Potential of Targeting PDE1C/2A for Suppressing Metastatic Ovarian Cancers				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-13-1-0122	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Shuang Huang E-Mail: shuanghuang@ufl.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Georgia Regents University Research Institute Augusta, GA				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT ERK signaling pathway has long been suggested as a therapeutic target for ovarian cancer progression and metastasis. In our previous studies, we showed that 1) high Erk activity is sensitive to the elevation of intracellular cAMP concentration; and 2) agents elevating cellular cAMP suppresses growth of aggressive ovarian cancer cells. This proposal is sought to 1) understand molecular mechanisms associated with forskolin/PDE2 inhibitor-induced apoptosis of aggressive ovarian cancer cells and 2) to evaluate the translation value of treating aggressive ovarian cancer cells with forskolin and PDE2 inhibitor in an intraperitoneal xenograft model. In first year of the funding, we showed that knockdown of PDE2A rendered ovarian cancer cells susceptible for forskolin-induced cell growth inhibition/apoptosis. We further showed that combined use of forskolin and Bay60-7550 (PDE2 inhibitor) downregulates the levels of Bcl2, survivin and phosphorylated Akt whereas induces the expression of Bim1. The effect of forskolin/Bay60-7550 is clearly mediated by PKA because PKA inhibitor H89 abolished growth inhibition caused by forskolin/Bay60-7550. Results from our first year study elucidate molecular mechanism underlying forskolin/PDE2 inhibitor-led ovarian cancer cell growth inhibition/apoptosis and built basis of testing forskolin/Bay60-7550 in ovarian cancer models.					
15. SUBJECT TERMS					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			USAMRMC
			UU		19b. TELEPHONE NUMBER (include area code)

Introduction.....	4
Body.....	5-6
Key Research Accomplishments.....	7
Reportable Outcomes.....	7
References.....	7
Appendices.....	7

Introduction


Ovarian cancer has the highest mortality rate among gynecological cancers. Due to the lack of symptoms with early stage disease and no effective screening strategies, ovarian tumors have become metastatic at the time of clinical diagnosis in 75% of ovarian cancer patients. Unfortunately, advances in surgical techniques and chemotherapy have not significantly improved the survival of ovarian cancer patients in past several decades. Therefore, the novel therapeutic approaches are urgently needed for treating metastatic ovarian cancers.

ERK signaling pathway plays a critical role in the survival and proliferation of ovarian cancer cells. It is thus expected that approaches interfering with ERK signaling pathway will lead to the suppression of ovarian cancer progression and metastasis. In our previous studies, we showed that 1) Erk activity is higher in aggressive ovarian cancer cells and is required for their survival; 2) high Erk activity is sensitive to the elevation of intracellular cAMP concentration; 3) combined use of forskolin and PDE2 inhibitor induces apoptosis of aggressive ovarian cancer cells. This proposal is 1) sought to understand molecular mechanisms associated with forskolin/PDE2 inhibitor-induced apoptosis of aggressive ovarian cancer cells and 2) to evaluate the translation value of treating aggressive ovarian cancer cells with forskolin and PDE2 inhibitor in an intraperitoneal xenograft model. In first year of the funding, we showed that knockdown of PDE2A rendered ovarian cancer cells susceptible for forskolin-induced cell growth inhibition/apoptosis. We further showed that combined use of forskolin and Bay60-7550 (PDE2 inhibitor) downregulates the levels of Bcl2, survivin and phosphorylated Akt whereas induces the expression of Bim1. The effect of forskolin/Bay60-7550 is clearly mediated by PKA because PKA inhibitor H89 abolished growth inhibition caused by forskolin/Bay60-7550. Results from our first year study elucidate molecular mechanism underlying forskolin/PDE2 inhibitor-led ovarian cancer cell growth inhibition/apoptosis and thus built basis of testing forskolin/Bay60-7550 in ovarian cancer models.

Body

Tasks of first year of this proposal are 1) Examine the effect of PDE1C and PDE2A-specific siRNAs on ovarian cancer cell growth inhibition/apoptosis (months 1-4); 2) Examine the effect of PDE1 and PDE2 inhibitors (8-methoxymethyl-IBMX and Bay60-7550) on ovarian cancer cell growth inhibition/apoptosis (months 5-8); 3) Determine potential involvement of PKA in PDE1/2 inhibitor-led ovarian cancer cell growth inhibition/apoptosis.

Task 1: We introduced PDE1C or PDE2A siRNAs into ovarian cancer ES2 and OVCAR5 cells and measured their effect on cell growth. Only slightly growth inhibitory effect was seen with




PDE2A siRNA in aggressive ovarian cancer cells. To determine if lack of growth inhibition by PDE siRNA is caused by poor accumulation of cellular cAMP in these cells, we treated these cells with 10 μ M forskolin two days after siRNA transfection. MTT assay showed that forskolin suppressed over 60% of cell growth in cells with PDE2A-knockdown but not PDE1C-knockdown in 3-day growth period. Silencing both PDE1C and PDE2A did not make forskolin more growth inhibitory. Moreover, forskolin alone only marginally inhibited growth of cells treated with control siRNA (Fig.1). Similar results were also generated with another four ovarian cancer cell lines (HEY, OCC1, OVCAR8 and SK-OV3) (data not shown).


These results suggest that forskolin can effectively ovarian cancer cells growth when PDE2A is blocked.

Task 2: ES2 and OVCAR5 cells were first treated with PDE2 inhibitor Bay60-7550 or PDE1 inhibitor 8-methoxymethyl-IBMX for 2 h followed by treatment of forskolin for 3 days. MTT assay clearly showed that Bay60-7550, but not 8-methoxymethyl-IBMX rendered cells responding to forskolin for growth inhibition (Fig.2A). Similar results were also generated with HEY, OCC1, OVCAR8 and SK-OV3 cells (data not shown). To determine whether growth inhibition was caused by cell death, we performed Annexin V/PI-staining on OVCAR5 cells treated with or without forskolin/Bay60-7550. Flow cytometry revealed a dramatic increase in apoptotic cells (Fig.2B). To elucidate molecular mechanism associated with forskolin/PDE2 inhibitor-induced apoptosis, we collected cell lysates from untreated OVCAR5 cells and OVCAR5 cells treated with forskolin/Bay60-7550 or forskolin/EHNA (another PDE2 inhibitor). Western blotting showed combined treatment but none of them alone led to reduction in the

abundance of Bcl2, survivin and phosphor-Akt while increased the level of Bim1 (Fig.2C). These results suggest that forskolin/PDE2 inhibitor treatment suppresses ovarian cancer cell



growth by inducing cell death through the inhibition of Bcl2/survivin/phosphor-Akt/and upregulation of Bim1.



Task 3: To determine the potential role of PKA in forskolin/Bay60-7550-led ovarian cancer cell growth inhibition/apoptosis, we pretreated ES2 and OVCAR5 cells with PKA inhibitor H89 for 2 h prior to the treatment of forskolin/Bay60-7550. MTT assay showed that H89 abolished at least 80% of forskolin/Bay60-7550-caused growth inhibition (Fig.3), thus confirming that PKA as the mediator for forskolin/Bay60-7550-led growth inhibitory effect in ovarian cancer cells.

Key Research Accomplishment

We found that 1) Inhibiting PDE2 makes ovarian cancer cells susceptible to forskolin-induced growth inhibition/apoptosis. 2) Forskolin/Bay60-7550-caused ovarian cancer cell growth inhibition/apoptosis is PKA-dependent.

Reportable Outcomes

Our study has built the basis for further testing forskolin/Bay60-7550 in murine tumor model for their anti-tumor effectiveness.

References

None

Appendices

N/A